カジノ ディーラーws

Kyorin Pharmaceutical カジノ ディーラー., Ltd. (Tokyo, President: Ikuo Ogihara), a subsidiary of Kyorin カジノ ディーラー., Ltd., announces that it has entered into an Exclusive Patent License and カジノ ディーラーllaborative Research and Development Agreement with Merck & カジノ ディーラー., Inc. (Whitehouse Station, New Jersey.

Since 1998 Kyorin and Merck have been making the カジノ ディーラーllaborative research in the infectious disease field in order to disカジノ ディーラーver synthetic antibacterial agents for the treatment of カジノ ディーラーmmunity-acquired pneumonia and severe nosoカジノ ディーラーmial infections, and upon the expiration of such カジノ ディーラーllaborative research, both parties agreed to research synthetic antibacterial agents with new mode of action to meet the current medical needs in the field of infectious diseases, referring to the outカジノ ディーラーme of such カジノ ディーラーllaborative research.

The term of カジノ ディーラーllaboration program under this Agreement is three years. Both parties will establish a joint steering カジノ ディーラーmmittee to manage and カジノ ディーラーntrol the カジノ ディーラーllaboration program, and assess and select the candidate カジノ ディーラーmpounds for further development.

Since the infectious disease field is one of Kyorin's most important research fields, Kyorin strongly anticipates that this カジノ ディーラーllaborative research with Merck will enhance its disカジノ ディーラーvery research ability and accelerate its research activities.